Table 1.
N = number of patients |
Age 10–13 yrs |
Age 14–17 yrs |
Age 18–27 yrs |
All patients |
---|---|---|---|---|
N = 33 | N = 18 | N = 12 | N = 63 | |
Boys (N) |
13 |
6 |
3 |
22 |
Girls (N) |
20 |
12 |
9 |
41 |
Subtype JIA N (%) |
3 (9.1) |
4 (22.2) |
1 (8.3) |
8 (12.7) |
Systemic |
3 (9.1) |
0 (0) |
0(0) |
3 (4.8) |
Oligo persistent |
9 (27.3) |
3 (16.7) |
3 (25.0) |
15 (23.8) |
Oligo extended |
3 (9.1) |
2 (11.1) |
2 (16.7 ) |
7 (11.1) |
Polyarticular RF+ |
14 (42.4) |
8 (44.4) |
5 (41.7) |
27 (42.9) |
Polyarticular RF- |
0 (0) |
1 (5.6) |
1 (8.3) |
2 (3.2) |
Enthesitis related Psoriatic arthritis |
1 (3.0) |
0 (0) |
0 (0) |
1 (1.6) |
Disease Duration in years (IQR) |
5.5 (6.0) |
10.5 (6.0) |
10.0 (18.0) |
8.0 (7.0) |
CHAQ (IQR) |
1,6 (0.8) |
1,4 (0.3) |
1,4 (0.6)_ |
1,5 (0.8) |
Sports performance (hours/week, IOR) |
2.0 (3.0) |
3.0 (8.0) |
2.5 (6.0) |
2.0 (3.0) |
BMI kg/m2 (IQR) |
17.9 (3.3) |
21.3 (4.5) |
19.8 (3.9) |
18.8 (4.7) |
Z-score VO2peak (IQR) |
−0.9 (1.5) |
−0.8 (1.6) |
−0.6 (1.7) |
−0.8 (1.3)** |
Z-score VO2peak/kg (IQR) |
−1.6 (1.7) |
−1.5 (2.1) |
−1.0 (2.1) |
−1.5 (1.9)** |
ESR mm (IQR) |
8.0 (10.0) |
9.5 (16.0) |
7.0 (14.0) |
8.0 (13.0) |
CRP mg/l (IQR) |
2.0 (5.0) |
6.0 (23.0) |
6.0 (5.0) |
5.5 (6.0) |
Haemoglobin mmol/l (IQR) |
8.0 (1.0) |
7.6 (1.0) |
8.7 (1.3) |
7.9 (1.3) |
Thrombocytes 10.9/l (IQR) |
315 (102) |
273 (102) |
290 (93) |
298 (83) |
DAS28 (IQR) |
1.7 (1.1) |
1.8 (1.9) |
1.5 (1.6) |
1.6 (1.2) |
JADAS 27 (IQR) |
3.6 (7.1) |
3.0 (22.9) |
2.6 (17.1) |
2.9 (9.0) |
VAS patient (IQR) |
0.2 (2.3) |
0.5 (3.1) |
0.5 (.6) |
0.5 (2.3) |
Number of swollen joints (IQR) |
0.0 (2.0) |
0.0 (3.0) |
0.0 (3.0) |
0.0 (4.4) |
Number of tender joints (IQR) |
0.0 (3.5) |
0.0 (4.0) |
0.0 (3.8) |
0.0 (4.1) |
Number of limited joints (IQR) | 1.5 (4.0) | 2.0 (5.0) | 2.5 (5.0) | 2.0 (4.0) |
All variables are expressed as median values unless otherwise stated.
** p < 0.01 significant difference compared to healthy age and sex related individuals.